arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Cardio Diagnostics Holdings, Inc.

CDIO
$1.67 ▼ -0.03 (-1.76%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
21 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cardio Diagnostics Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.7M
Dividend Yield
Revenue Growth 185.1%
Op. Margin
ROIC -15.8%
FCF / Share $-0.55
Trailing P/E
Price / Book 0.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

21-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.68K
↑ +185.1%
Net Income Profit after all expenses
$-1.79M
↓ -9.4%
FCF / Share Free cash flow per share
$-0.55
↑ +34.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Financial Health
7
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 21 quarters